Filing Analysis
Medifast, Inc. filed an 8-K to announce its second quarter 2026 financial results for the period ended June 30, 2026. The filing serves as a formal notification that earnings results have been released via press release.
📋 Key Facts
- Earnings announcement for Q2 2026 (period ended June 30, 2026).
- Report filed on August 3, 2026.
- Information furnished under Item 2.02 is not considered 'filed' for purposes of Section 18 liability.
Medifast, Inc. announced the rebranding of its wholly-owned subsidiary, OPTAVIA, to 'Trilivy,' positioning it as a comprehensive metabolic health system.
📋 Key Facts
- Rebranding of OPTAVIA (wholly-owned subsidiary) to Trilivy.
- The new brand is described as a 'comprehensive metabolic health system'.
- Filing date: July 17, 2026.
Medifast Inc. announced the resignation of Jason L. Groves, Esq., who served as Chief Legal Officer & Corporate Secretary, effective May 29, 2026. The company has entered into a separation agreement providing a one-month base salary severance payment.
📋 Key Facts
- Jason L. Groves resigned as Chief Legal Officer & Corporate Secretary effective May 29, 2026.
- A separation and release agreement was signed on May 31, 2026.
- Severance consists of a one-time lump sum payment equal to one month of annual base salary.
- The company has commenced a search for a permanent replacement.
Medifast, Inc. announced that Nicholas Johnson will succeed Daniel Chard as Chief Executive Officer, effective June 1, 2026, with Mr. Chard transitioning to non-executive Chairman. Additionally, stockholders approved an amendment to the 2012 Share Incentive Plan to increase authorized shares by 250,000.
🚩 Red Flags
- Shareholder dilution from the 250,000 share increase in the 2012 Share Incentive Plan.
- Director nominee Scott Schlackman received a notable amount of opposition with 795,603 'Against' votes compared to 3,842,303 'For' votes.
📋 Key Facts
- Nicholas Johnson (age 46) appointed CEO effective June 1, 2026.
- Outgoing CEO Daniel Chard transitions to non-executive Chairman of the Board.
- Mr. Johnson's compensation includes a $600,000 base salary, 100% target bonus, and 250% LTI target, representing a 69% increase in total compensation from his prior role as President.
- Stockholders approved an increase of 250,000 shares authorized under the Amended and Restated 2012 Share Incentive Plan.
- RSM US LLP was ratified as the independent auditor for the fiscal year ending December 31, 2026.
Medifast, Inc. announced its financial results for the first quarter ended March 31, 2026. The announcement was made via a press release furnished under Item 2.02 of the 8-K filing.
📋 Key Facts
- The company reported earnings for the first quarter ended March 31, 2026.
- The press release was issued and the 8-K was filed on May 4, 2026.
- The filing was signed by James P. Maloney, the Chief Financial Officer.
Medifast, Inc. entered into a Cooperation Agreement with activist investor Steamboat Capital Partners LLC on March 19, 2026. The agreement settles potential board disputes by appointing two Steamboat designees to the Board of Directors in exchange for standstill and voting commitments.
🚩 Red Flags
- Activist investor intervention (Steamboat Capital Partners) typically indicates shareholder dissatisfaction with management or stock performance.
- The filing includes multiple 8-K items (1.01, 5.02, 7.01), which often signals complex corporate developments.
📋 Key Facts
- Medifast will nominate seven individuals for election at the 2026 Annual Meeting, including two Steamboat Designees: Parsa Kiai and Jeffrey Rose.
- The company committed to nominating the same two Steamboat Designees for the 2027 Annual Meeting.
- Steamboat Capital is subject to a standstill period ending three months after the 2027 Annual Meeting.
- During the standstill, Steamboat must vote its shares in favor of Board-nominated directors and other Board recommendations.
- The agreement was signed by CFO James P. Maloney on March 20, 2026.
Medifast, Inc. issued an 8-K to announce its financial results for the fourth quarter and full fiscal year ended December 31, 2025.
📋 Key Facts
- Earnings release covers Q4 and Full Year 2025.
- Report date: February 17, 2026.
- The information is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 liability.
Medifast announced a significant leadership reshuffle involving the departure of its Chief Business Operations Officer and a planned transition of its CEO to non-executive Chairman. The company is also implementing internal promotions as part of a succession planning process.
🚩 Red Flags
- Multiple high-level executive changes occurring simultaneously (CEO transition, CBOO departure, CFO role expansion).
- Significant reduction in CEO compensation/incentives as part of the transition plan.
- Succession planning volatility: While described as planned, the simultaneous exit of a C-suite officer and the shift in CEO role can create operational uncertainty.
📋 Key Facts
- Anthony Tyree (Chief Business Operations Officer) departing effective December 31, 2025; receiving ~$706,984 in salary and target bonus plus prorated equity/benefits.
- Nicholas Johnson promoted to President of Medifast effective January 5, 2026, overseeing field, technology, marketing, scientific, clinical, and product teams.
- CEO Daniel Chard transitioning to non-executive Chairman effective June 1, 2026; compensation reduced (Salary: $1M to $800k; Target LTIC: $4.6M to $2.4M).
- CFO James Maloney to take on leadership of the supply chain function.
- All departures and transitions are stated to be unrelated to disagreements with management or company practices.
Medifast, Inc. has filed an 8-K to announce its third quarter 2025 financial results for the period ended September 30, 2025.
📋 Key Facts
- Earnings announcement date: November 3, 2025
- Reporting period: Third Quarter ended September 30, 2025
- The filing includes a press release (Exhibit 99.1) containing the financial results.
Medifast, Inc. filed an 8-K to announce its second quarter 2025 financial results for the period ended June 30, 2025.
📋 Key Facts
- Earnings announcement for Q2 2025 (ended June 30, 2025) issued on August 4, 2025.
- The filing includes a press release as Exhibit 99.1 containing the financial results.
Medifast, Inc. reported the results of its 2025 Annual Meeting of Stockholders, which included the re-election of all seven board members and the approval of an amended share incentive plan.
🚩 Red Flags
- Significant opposition to executive compensation ('Say on Pay' vote) with approximately 2.47 million votes against, indicating potential shareholder dissatisfaction regarding pay structures.
📋 Key Facts
- Stockholders approved an amendment to the 2012 Share Incentive Plan to increase authorized shares by 550,000.
- All seven nominated directors were re-elected to the Board of Directors.
- RSM US LLP was ratified as the Company's Independent Registered Public Accounting Firm for fiscal year ending Dec 31, 2025.
- The 'Say on Pay' advisory vote regarding executive compensation was approved by a significant margin (3.58M For vs 2.47M Against).
- The Amended 2012 Plan was approved by stockholders.
Medifast, Inc. issued an 8-K to announce its first quarter 2025 financial results for the period ended March 31, 2025.
📋 Key Facts
- Earnings release date: April 28, 2025
- Reporting period: First Quarter ended March 31, 2025
- The filing is a standard earnings announcement under Item 2.02.
Medifast, Inc. has issued an 8-K to announce its financial results for the fourth quarter and full fiscal year ended December 31, 2024.
📋 Key Facts
- Earnings release date: February 18, 2025
- Reporting period: Q4 and Full Year 2024 (ended Dec 31, 2024)
- The filing is for informational purposes under Item 2.02 and does not constitute a formal 'filing' subject to Section 18 liabilities.
Medifast, Inc. terminated its $225 million secured revolving credit facility with Citibank, N.A. and simultaneously released its Q3 2024 financial results.
🚩 Red Flags
- None identified; termination occurred without penalty and with zero outstanding debt.
📋 Key Facts
- Terminated Credit Agreement dated April 13, 2021 (amended May 31, 2022).
- The facility provided a secured revolving credit line of up to $225 million plus a $20 million letter of credit sublimit.
- As of termination date, the Company had zero borrowings under this facility.
- No premiums or early termination penalties were incurred.
- Company was in full compliance with all covenants at the time of termination.
- Q3 2024 financial results were released on November 4, 2024.
Medifast, Inc. filed an 8-K to announce its second quarter 2024 financial results for the period ended June 30, 2024.
📋 Key Facts
- Report date: August 5, 2024
- Reporting period: Second Quarter ended June 30, 2024
- The filing is a standard earnings release announcement (Item 2.02)
- Information furnished is not considered 'filed' for purposes of Section 18 liability
Medifast, Inc. held its 2024 annual meeting of stockholders on June 19, 2024. Stockholders approved several key items, including the re-election of all seven directors and an amendment to the 2012 Share Incentive Plan.
📋 Key Facts
- Annual Meeting held on June 19, 2024.
- Stockholders approved an amendment to the 2012 Share Incentive Plan, increasing authorized shares by 515,000.
- Plan Amendment includes a new one-year minimum vesting provision on all awards and a non-employee director award limit.
- All seven nominated directors (Jeffrey J. Brown, Daniel R. Chard, Elizabeth A. Geary, Michael A. Hoer, Scott Schlackman, Andrea B. Thomas, and Ming Xian) were re-elected.
- Stockholders ratified the appointment of RSM US LLP as the independent registered public accounting firm for fiscal year 2024.
- Advisory vote on executive compensation (Say-on-Pay) was approved.
Medifast, Inc. issued an 8-K to announce its first quarter 2024 financial results for the period ended March 31, 2024.
📋 Key Facts
- Report date: April 29, 2024
- Reporting period: First Quarter ended March 31, 2024
- The filing is a standard earnings announcement via press release (Exhibit 99.1)
- Information is furnished but not 'filed' for purposes of Section 18 liability
Medifast, Inc. issued an 8-K to announce its financial results for the fourth quarter and full fiscal year ended December 31, 2023.
📋 Key Facts
- Report date: February 20, 2024
- Reporting period: Fourth quarter and full fiscal year ended December 31, 2023
- The filing includes a press release (Exhibit 99.1) containing the earnings results
- Information is furnished under Item 2.02 but not 'filed' for purposes of Section 18 liability